265 results on '"Luettgen, Joseph M."'
Search Results
2. Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits
3. Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group
4. In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa
5. Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy
6. Preclinical metabolism and disposition of an orally bioavailable macrocyclic FXIa inhibitor
7. Anticoagulants
8. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor
9. Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits
10. Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa
11. Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability
12. Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species
13. Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups
14. Inhibition of Factor Xa Reduces Ischemic Brain Damage After Thromboembolic Stroke in Rats
15. Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors
16. Macrocyclic factor XIa inhibitors
17. Macrocyclic inhibitors of Factor XIa: Discovery of alkyl-substituted macrocyclic amide linkers with improved potency
18. Neutral macrocyclic factor VIIa inhibitors
19. Synthesis and P1′ SAR exploration of potent macrocyclic tissue factor-factor VIIa inhibitors
20. Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)
21. Novel phenylalanine derived diamides as Factor XIa inhibitors
22. Factor XIa Inhibitors as New Anticoagulants
23. First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects
24. Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)
25. Design and synthesis of potent, selective phenylimidazole-based FVIIa inhibitors
26. Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties
27. Pyridine and pyridinone-based factor XIa inhibitors
28. Abstract TMP117: Preclinical and Early Clinical Characterization of a Parenterally Administered Direct Factor XIa Inhibitor
29. Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker
30. Design and Synthesis of Novel Meta-Linked Phenylglycine Macrocyclic FVIIa Inhibitors
31. Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors
32. Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups
33. Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties
34. Nonbenzamidine acylsulfonamide tissue factor–factor VIIa inhibitors
35. Discovery and gram-scale synthesis of BMS-593214, a potent, selective FVIIa inhibitor
36. Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF–FVIIa inhibitors
37. Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa–Tissue Factor Complex
38. Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors
39. Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2′ Moiety
40. Phenylimidazoles as Potent and Selective Inhibitors of Coagulation Factor XIa with in Vivo Antithrombotic Activity
41. Phenyltriazolinones as potent factor Xa inhibitors
42. Tetrahydroquinoline Derivatives as Potent and Selective Factor XIa Inhibitors
43. Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors
44. Highly efficacious factor Xa inhibitors containing α-substituted phenylcycloalkyl P4 moieties
45. Structure–activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors
46. Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: Discovery of novel, highly potent inhibitors of Factor Xa
47. Structure–activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties
48. Sulfonamidolactam inhibitors of coagulation factor Xa
49. Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma
50. Inhibition of Factor XIa as a New Approach to Anticoagulation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.